| 发明名称 |
Oral Delivery of Therapeutically Effective LNA Oligonucleotides |
| 摘要 |
The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer. |
| 申请公布号 |
US2016032289(A1) |
申请公布日期 |
2016.02.04 |
| 申请号 |
US201514886860 |
申请日期 |
2015.10.19 |
| 申请人 |
Roche Innovation Center Copenhagen A/S |
发明人 |
Hardee Gregroy;Straarup Ellen Marie;Wickstrom Lindholm Marie;Orum Henrik;Frydenlund Hansen Henrik |
| 分类号 |
C12N15/113;A61K9/00 |
主分类号 |
C12N15/113 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for inhibiting a miRNA comprising orally administering to a patient a composition comprising an LNA oligomer that targets the miRNA and a penetration enhancer, wherein the miRNA is selected from the group consisting of: miR19b, miR21, miR 122, miR142 a7b, miR 155, and miR 375. |
| 地址 |
Hoersholm DK |
